NCT06142253 Water-based Activity to Enhance Recovery in Long COVID-19
| NCT ID | NCT06142253 |
| Status | Recruiting |
| Phase | — |
| Sponsor | VA Office of Research and Development |
| Condition | Long COVID |
| Study Type | INTERVENTIONAL |
| Enrollment | 50 participants |
| Start Date | 2024-12-01 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 50 participants in total. It began in 2024-12-01 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This two-year study will evaluate the feasibility and safety of an exercise + cognitive training program to improve neurological symptoms of long-COVID. This is a two-phased trial: 1) an exercise phase and 2) a cognitive training phase. The exercise phase will be an aquatic based exercise program. A combination exercise + memory training programs designed for persons with cognitive impairment have significantly improved memory more than other single intervention groups (exercise only, cognitive training only) and given the success of combination training programs with healthy adults, it is important to adapt these programs for persons with neurological symptoms of long-COVID.
Eligibility Criteria
Inclusion Criteria: * Veterans, age 18 to 89, of any racial or ethnic group * Previous COVID-19 infection at least 6 months after diagnosis documented in clinical record * Persistent neurological symptoms (e.g., "brain fog", cognitive impairment) occurring within 3 months of onset of COVID-19 infection and lasting at least 8 weeks in duration * Visual and auditory acuity to allow neuropsychological testing * Willingness to participate in clinical trial for 8 months * Approval by Primary Care Provider to participate in water-based physical exercise Exclusion Criteria: Psychiatric Exclusions * Current, uncontrolled severe psychotic disorder determined by the Mini International Neuropsychiatric Interview (MINI) Medical Exclusions * History of neurological (e.g., multiple sclerosis, seizure disorder, stroke,) neurodegenerative (e.g., Parkinson's disease, Alzheimer's disease) or system illness affecting CNS function (e.g., liver failure, kidney failure, congestive heart failure, systemic cancer) occurring before COVID-19 diagnosis * Current severe cardiac disease (e.g., uncontrolled atrial fibrillation, defined as mean 24 hour heart rate \>85 beats/min, or 24 hour maximal ventricular rate \>150 beats/min; uncontrolled ventricular arrhythmias, defined as recurrent ventricular tachycardia \>3 beats in succession, or 24 hour PVC count \>20%; active pericarditis or myocarditis; Class III/IV heart failure and / or ejection fraction \< 20%; thrombophlebitis; pulmonary disease with a drop in O2 Sat with exercise to 90% without oxygen; embolism within past 6 months) * Inability to participate in an exercise stress test * Inability to read, verbalize understanding and voluntarily sign the Informed Consent
Contact & Investigator
Jennifer Kaci Fairchild, PhD
PRINCIPAL INVESTIGATOR
VA Palo Alto Health Care System, Palo Alto, CA
Frequently Asked Questions
Who can join the NCT06142253 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 89 Years, studying Long COVID. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06142253 currently recruiting?
Yes, NCT06142253 is actively recruiting participants. Contact the research team at JenniferKaci.Fairchild@va.gov for enrollment information.
Where is the NCT06142253 trial being conducted?
This trial is being conducted at Palo Alto, United States.
Who is sponsoring the NCT06142253 clinical trial?
NCT06142253 is sponsored by VA Office of Research and Development. The principal investigator is Jennifer Kaci Fairchild, PhD at VA Palo Alto Health Care System, Palo Alto, CA. The trial plans to enroll 50 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.